Nevanac (nepafenac)
- Region
- 🇪🇺 EU
- Active substance
- nepafenac
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Pain, Postoperative; Ophthalmologic Surgical Procedures
- EU approval
- Tue 11 Dec 2007
- Application
- EMEA/H/C/000818
- ATC
- S01BC10
- Official record
- www.ema.europa.eu
Indication
Nevanac is indicated for: prevention and treatment of postoperative pain and inflammation associated with cataract surgery; reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
Regulatory milestones
No milestones recorded in the last year.
Follow Nevanac
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.